Abstract-Circulating endothelial progenitor cells (EPCs) are reduced in hypertension, which inversely correlates with its mortality. Deoxycorticosterone acetate (DOCA)-salt hypertension features elevated endothelin (ET) 1 and oxidative stress. We tested the hypothesis that ET-1 induces EPC dysfunction by elevating oxidative stress through the ET A /NADPH oxidase pathway in salt-sensitive hypertension. Both ET A and ET B receptors were expressed in EPCs, but only ET A receptors were significantly increased in EPCs of DOCA-salt rats. EPC number and function were reduced in DOCA-salt rats compared with sham controls, and both were reversed by in vivo blockade of ET A receptors or NADPH oxidase. The enzymatic activities of NAPDH oxidase and its subunits gp91 phox , p22 phox , and Rac1 were augmented in EPCs of DOCA-salt rats, with concomitantly decreased antioxidant enzymes manganese superoxide dismutase, copper-zinc superoxide dismutase, and glutathione peroxidase 1. Reactive oxygen species level was elevated in EPCs from DOCA-salt rats, accompanied by increased EPC telomerase inactivation, senescence, and apoptosis, which were rescued by ET A or NADPH oxidase blockade. Cell therapy of normal or treated DOCA EPCs, but not untreated DOCA EPCs, significantly increased capillary density and blood perfusion in ischemic hindlimbs of DOCA-salt rats. p53 and Bax/Bcl-2 ratios were increased in EPCs of DOCA-salt rats, which were reversed by ET A antagonist, NADPH oxidase inhibitor, or polyethylene glycol-superoxide dismutase. Finally, in ET B -deficient rats, plasma ET-1 was elevated, and EPC number and telomerase activity were diminished. These results demonstrate, for the first time, that both ET-1 activation of ET A /NADPH oxidase pathway and diminished antioxidants critically contribute to EPC reduction and dysfunction via increased oxidative stress in salt-sensitive hypertension. (Hypertension. 2012;59:1037-1043.) • Online Data Supplement Key Words: endothelin 1 Ⅲ oxidative stress Ⅲ NADPH oxidase Ⅲ endothelial progenitor cell Ⅲ hypertension E ndothelial dysfunction contributes to the pathogenesis and progression of hypertension and is an independent predictor of cardiovascular risk. 1 The balance between endothelial injury and recovery is important to reduce cardiovascular incidences. 1,2 Endothelial progenitor cells (EPCs) can differentiate into mature endothelial cells and regenerate the injured endothelium. 2,3 There has been accumulating evidence for reduced availability and impaired function of EPCs in the presence of cardiovascular risks.
1,2
Endothelial progenitor cells (EPCs) can differentiate into mature endothelial cells and regenerate the injured endothelium. 2, 3 There has been accumulating evidence for reduced availability and impaired function of EPCs in the presence of cardiovascular risks. [3] [4] [5] Among them, hypertension is a strong predictor of EPC migratory impairment. 5, 6 Both clinical and animal studies have indicated that hypertension is inversely correlated with EPC reduction and/or dysfunction. [7] [8] [9] However, investigations of in vivo EPC biology under hypertensive condition are limited, and the mechanisms underlying EPC dysfunction in hypertension remain poorly understood.
Deoxycorticosterone acetate (DOCA)-salt hypertension exhibits low renin, salt-sensitive but elevated arterial endothelin (ET) 1 and oxidative stress, 10 due to vascular NADPH oxidase activation and superoxide formation via the ET A receptors, 10 resulting in endothelial dysfunction. 10 Elevated arterial ET-1 levels in DOCA-salt rats led to NADPH oxidase activation and superoxide formation via the ET A receptors, 10 resulting in endothelial dysfunction. In contrast, ET B receptors may protect against vascular injuries in this setting. 11 Circulating EPCs are important backups for endothelium integrity and function. In this study, we tested the hypothesis that ET-1 activation of ET A /NADPH oxidase pathway and diminished antioxidants both critically contribute to EPC dysfunction in DOCA-salt hypertension. Our findings may provide a mechanistic basis for restoring EPC number and function to combat endothelial dysfunction in hypertension.
Methods
All of the methods and data analysis are described in the online-only Data Supplement.
Results

Characterization of Bone Marrow-Derived EPCs
Bone marrow-derived EPCs used in the present study were characterized by flow cytometry, Dil-acLDL/lectin double staining and Western blot, which were presented in the online-only Data Supplement (Tables S1 and S2 and Figure S1 ).
ET A and ET B Receptor Expression in EPCs
The mRNA levels of ET A and ET B receptors were detected in normal EPCs (1.00Ϯ0.28 versus 1.27Ϯ0.68; Pϭ0.732; nϭ4 -6), which were further confirmed by immunohistochemistry ( Figure S2 ). Furthermore, the expression of ET A receptors in EPCs of DOCA-salt rats was significantly increased compared with sham controls, whereas there were no significant differences in the expressions of ET B receptors in EPCs between DOCA-salt and sham rats ( Figure 1 ).
Activation of NADPH Oxidase and Increased Reactive Oxygen Species in EPCs of DOCA-Salt Rats
Rac1, gp91 phox , and p22 phox proteins were significantly increased in EPCs of DOCA-salt rats compared with sham controls ( Figure S3A ). Consistently, NADPH oxidase activity was significantly increased in EPCs from DOCA-salt rats compared with sham rats. In vivo treatment with ET A antagonist (ABT-627) or NADPH oxidase inhibitors (Apocynin) blunted the activation of NADPH oxidase ( Figure 2A ). When EPCs of DOCA-salt rats were transfected with the dominant-negative Rac1 (DNRac1), which inhibits the key NADPH oxidase subunit Rac1, their NADPH activities were significantly decreased. The same effect was not observed in ␤-galactosidase-transfected EPCs ( Figure  2A ). Meanwhile, the intracellular reactive oxygen species (ROS) in DOCA-derived CD34 ϩ /Flk-1 ϩ progenitor cells was significantly elevated compared with that in sham rat 
Antioxidant Enzyme in the EPCs of DOCA-Salt Rats
The expressions of major antioxidant enzymes were measured in EPCs from sham and DOCA-salt rats. Except for catalase, the expressions of manganese superoxide dismutase (MnSOD), copper-zinc superoxide dismutase (CuZnSOD), and glutathione peroxidase 1 (GPx-1) in EPCs from DOCA-salt rats were significantly decreased when compared with those from sham rats. In vivo blockade of ABT-627 or Apocynin for 4 weeks significantly reversed the expressions of the decreased antioxidant ( Figure 3 ).
EPC Dysfunctions in DOCA-Salt Rats
The tube formation capacity of EPCs was significantly impaired in DOCA-salt rats compared with sham controls. In vivo treatment with ABT-627 or Apocynin significantly preserved EPC tube formation capacity (Figure 4) . In addition, the adhesion activity of EPCs from DOCA-salt rats was decreased by 50% to 60% compared with sham controls, which was reversed by in vivo blockade of ET A receptors (nϭ4 -8; PϽ0.05) but not by Apocynin (nϭ3 in Apocynin group and nϭ5 in DOCA group; Pϭ0.7234).
Increased EPC Apoptosis and Senescence in DOCA-Salt Rats
Both apoptosis and senescence were significantly increased in EPCs from DOCA-salt rats, which were prevented in rats treated with ABT-627 or Apocynin ( Figure 5A and 5B). The expressions of apoptosis-related proteins were detected in EPCs. p53 expression in EPCs from DOCA-salt rats was significantly increased and accompanied by upregulation of proapoptotic Bax and downregulation of antiapoptotic Bcl-2 as compared with sham controls. The ratio of Bax/Bcl-2 was significantly increased by Ϸ2-fold in the EPCs of DOCA-salt rats. The above effects were reversed by chronic blockades of ET A receptors or NADPH oxidase ( Figure 5C and Figure S3C and S3D). The ROS scavenger, polyethylene glycol-superoxide dismutase (PEG-SOD, 100 U/mL, 24 hours) can reverse these effects ( Figure S3B) . Consistently, the telomerase activity in the EPCs of DOCA-salt rats was decreased by Ϸ70% compared with sham rats, which was rescued after in vivo treatment with ABT-627 or Apocynin for 4 weeks ( Figure 5D ).
EPC Therapy Restored Impaired Angiogenesis in DOCA-Salt Hypertensive Rats
Serial blood flow measurements by laser Doppler showed that limb perfusion recovery was severely delayed and impaired in DOCA-salt rats compared with sham rats ( Figure  6A ). The ratio of perfusion in ischemia relative to that in nonischemic hindlimb was 0.18Ϯ0.04 for DOCA rats versus 0.29Ϯ0.02 for sham rats at day 7 and 0.27Ϯ0.06% versus 0.62Ϯ0.05% at day 14, respectively ( Figure 6B ). To determine the effects of EPCs on blood flow reperfusions after the DOCA-salt regiment, 1ϫ10 7 EPCs were injected intramus- cularly into anterior tibial muscles 24 hours after femoral artery excision. The sham EPC implanted group significantly improved blood flow perfusion in DOCA-salt ischemia limbs from day 7 until day 14 (0.51Ϯ0.03 versus 0.27Ϯ0.06). Implantation with EPCs from ABT-627-treated DOCA rats or EPCs treated with DNRac1 significantly accelerated delayed reperfusion in ischemic hind limbs from day 7 to day 14. In contrast, implantation of DOCA EPCs improved the ischemic limb reperfusion at day 7, but they failed to improve the reperfusion in the DOCA-salt ischemia limb at day 14 (0.33Ϯ0.04 versus 0.27Ϯ0.06; Pϭ0.849; Figure 6B and 6C). The capillary density of ischemia hindlimb was significantly deceased in DOCA-salt rats compared with sham rats at day 14. EPCs from sham rats significantly increased the capillary number in ischemia hindlimb compared with the untreated DOCA rats ( Figure 6D and 6E) . Meanwhile, EPCs from ABT-627-treated DOCA rat or EPCs treated with DNRac1 restored capillary density in DOCA rats as well. To investigate whether implanted EPCs incorporate into existing vessels to participate in angiogenesis in hindlimb ischemia, 5-bromodeoxyuridine (BrdU)-labeled EPCs were injected intramuscularly into the anterior tibial muscle. Some BrdUpositive cells (red fluorescence) integrated into the CD31-positive vessels (green fluorescence), whereas the remaining 5-bromodeoxyuridine-positive cells were found in perivascular spaces or the matrix between muscle fibers surrounding the vessels ( Figure 4S ). Figure  S5B ). On day 28, average systolic blood pressure was further increased in DOCA-salt rats compared with sham controls ( Figure S5A) . However, the level of circulating CD34 ϩ /Flk-1 ϩ progenitor cells in DOCA-salt rats was reduced by 50% ( Figure  S5B ). In vivo blockade of ET A receptors, inhibition of NADPH oxidase, or diuretic (all in drinking water) for 4 weeks significantly lowered blood pressure and reserved circulating EPCs in DOCA-salt rats ( Figure S5C and S5D).
Effects of ET
EPC Number and Telomerase Activity in ET B Receptor-Deficient Rats
The circulating CD34ϩ/Flk-1ϩ progenitor cell level was significantly decreased in ET B receptor-deficient (ET B Ϫ/Ϫ ) rats compared with ET B ϩ/ϩ rats ( Figure S6A ). The telomerase activity in EPCs was also significantly reduced in ET B Ϫ/Ϫ rats ( Figure S6B ), paralleled with elevated systolic blood pressure (129Ϯ0.9 versus 151Ϯ1.2 mmHg; nϭ6; PϽ0.05) and plasma ET-1 levels (3.61Ϯ0.14 versus 5.17Ϯ0.26 pg/mL; nϭ6; PϽ0.05).
Direct Effects of ET A Receptor Antagonist and NADPH Oxidase Inhibitor on EPCs
ET-1-induced EPC reduction and NADPH oxidase activation were reversed by pretreatment with the ABT-627 or Apocynin. Transfection of EPCs with DNRac1, which inhibits the key NADPH oxidase subunit Rac1, blunted ET-1-induced EPC reduction and NADPH oxidase activity ( Figure S7A through S7C). Consistently, ROS level and apoptosis in normal EPCs were significantly increased after ET-1 treatment in vitro, which was abolished by pretreatment of ABT-627 or Apocynin ( Figure  S7D and S7E). Telomerase activity was markedly reduced in ET-1-treated normal EPCs, which were rescued by ABT-627 or Apocynin pretreatment ( Figure S7F ).
Discussion
The present study demonstrates for the first time that in DOCA-salt hypertension: (1) both ET A and ET B receptors are expressed in rat EPCs, and the expression of ET A receptors is significantly increased; (2) in vivo EPC angiogenesis is significantly impaired; (3) ET A -mediated NADPH oxidase activation leads to decreased EPC number and function; and (4) blockade of the ET A /NADPH oxidase pathway rescues EPC number and function.
Seven-day cultured EPCs used in the present study are heterogeneous populations containing progenitor cells with the potency differentiating into endothelial cells, as we have shown recently. 4 A number of clinical and animal studies have shown that the number and function of EPCs are decreased in hypertension. We showed that EPCs from DOCA-salt rats failed to promote capillary formation and blood flow recovery, whereas EPCs from DOCA-salt rats with ET A receptors or NADPH oxidase blockade significantly restored peripheral perfusion. Of note, while the capillary density in DOCA-EPC-implanted hindlimbs was enhanced, blood reperfusion was not proportionally improved after DOCA-EPC implantation on day 14, suggesting that the newly formed capillaries on DOCA-EPC implantation are not functional, leading to impaired angiogenesis and reduced reperfusion. We demonstrated previously that EPCs from DOCA-salt mice secrete thrombospondin 1 (a well-documented antiangiogenic factor) inhibiting Matrigel tube formations, which can be reversed by antioxidant treatments. 12 Thus, it is possible that altered EPC paracrine functions impair their ability in angiogenesis in DOCA-salt hypertension.
An important finding in the present study is the presence of ET receptors on rat early cultured EPCs. ET-1, as a major humoral contributor to the development of DOCA-salt hypertension, exerts its biological effects through binding to 2 G protein-coupled membrane receptors in a mature vascular system, namely, ET A and ET B subtypes. 13 Decreased circulating EPC number and telomerase activity were found in ET B receptor deficiency (ET B Ϫ/Ϫ ) rats that possess a phenotype of increased plasma ET-1 levels (because of the lack of ET-1 clearance), increased ROS level, and hypertension. 14 
These data indicate that elevated ET-1 in ET B
Ϫ/Ϫ rats may inactivate EPC telomerase activity and reduce EPC number through the unmasked effect on ET A receptors. Our study provides first evidence that both ET A and ET B receptors are expressed in rat EPCs. More importantly, the upregulated expression of ET A receptors, but not ET B receptors, suggests that ET A receptors may be the therapeutic target for EPC dysfunction in salt-sensitive hypertension. It has been reported that protein kinase C induces ET A receptors at a transcriptional level in rat fibroblasts 15 or in cardiac cells from DOCA-salt hypertensive rats. 16 However, whether these possibilities exist in EPCs remain unknown.
NADPH oxidase is a complex enzyme with multiple membrane and cytosolic subunits, and pharmacological interventions are rather limited and often difficult for specific inhibition of the enzyme subunits. 17 To this end, we transfected EPCs with the DNRac1 by adenoviral vectors to abrogate endogenous Rac1 expression, a key GTPase component of the NADPH oxidase complex. 1, 10 Our results show that excessive intracellular ROS in EPCs were dominantly generated by activated NADPH oxidase in DOCA-salt rats. Furthermore, blockades of ET A receptors with ABT-627 significantly inhibited NADPH oxidase activity in EPCs from DOCA-salt rats. This evidence from the present study suggests that ET A /NADPH oxidase is a potential pathway involved in EPC dysfunction in DOCA-salt hypertension.
Increased apoptotic and senescence EPCs were observed in DOCA-salt rats, suggesting that some molecules controlling cell survival and cell cycle may be the downstream targets in the ET A /NADPH oxidase pathway. Telomerase protects EPCs from senescence and improves their survival and regenerative properties against excessive ROS, 8,9,18 whereas the activity of telomerase in EPCs from DOCA-salt rats was markedly decreased, which partially contributes to impaired EPC angiogenic functions. In addition, the apoptosis-related molecules (p53 and Bax) were upregulated in DOCA EPCs, A, Representative images of hindlimb blood flow analyzed by laser Doppler perfusion imaging 14 days after transplantation. Color-coded images represent blood flow distribution. Low or no perfusion is displayed as dark blue, whereas highest perfusion is displayed as yellow or red. Seven-day cultured bone marrow-derived EPCs were used for cell therapy. Preoperation shows an intact hindlimb blood flow before femoral ligation artery surgery; postoperation, the hindlimb blood flow right after surgery; sham, sham rats; DOCA, DOCA rats; DOCAϩSham-EPCs, DOCA rats treated with EPCs from sham rats; DOCAϩDOCA-EPCs, DOCA rats treated with EPCs from DOCA rats; DOCAϩABT-EPCs, DOCA rats treated with EPCs from ABT-627 rats; DOCAϩDNRac1-EPCs, DOCA rats treated with DNRac1 EPCs. B and C, Quantitative analysis of blood flow in hindlimb expressed as perfusion ratio of ischemic hindlimb:nonischemic limb. A 2-way repeatedmeasures ANOVA with Bonferroni posttest was used to analyze blood flow perfusion in hindlimb ischemia models, and a significant overall difference was detected (PϽ0.05); nϭ5 for each group. The perfusion ratios of ischemic:nonischemic limb of sham and DOCA-salt rats representing the baseline were the same for B and C (*PϽ0.05 DOCA rats vs sham rats Although ET A receptor antagonism or NADPH oxidase inhibition could preserve the EPC number and its resistance to oxidative stress in DOCA-salt rats, the question remained regarding their direct antihypertensive effect on EPCs. To address this issue, we treated the DOCA-salt rats with the diuretic trichlormethiazide, a nonselective blood pressurelowering agent, for 4 weeks and found that trichlormethiazide failed to rescue the circulating EPC number in DOCA-salt rats despite its blood pressure-lowering effect. A recent study also showed that diuretics did not reverse the EPC number in spontaneously hypertensive rats when the blood pressure is reduced. 19 In addition, it is important to note that, although the systolic blood pressure was markedly reduced in DOCA-salt rats after in vivo ET A receptor blockade or NADPH oxidase inhibition, it was significantly higher (ie, Ϸ30 mmHg) compared with sham rats. In contrast, the number of circulating EPCs in the 2 groups of pharmacological intervention maintained the similar level to that of sham rats. Moreover, inhibition of ET A receptors or NADPH oxidase also ameliorated ET-1-induced EPC reduction in vitro, without the compounding effect of the blood pressure. Finally, we found that the circulating EPCs were increased at the beginning of the blood pressure elevation, which suggests that high blood pressure itself may not decrease circulating EPCs in DOCA-salt rats and the elevation in the number of EPCs in the beginning of the DOCA-salt regimen may be attributed to increased compensation of EPC mobilization from the bone marrow. Thus, inhibition of ET-1/ET A -NADPH oxidase-induced oxidative stress, more than blood pressure reduction, may account for the preservation of circulating EPC number in DOCA-salt rats.
Perspectives
The present study demonstrates, for the first time, that ET-1 activation of ET A /NADPH oxidase pathway and diminished antioxidants both critically contribute to EPC reduction and dysfunction via increased oxidative stress in salt-sensitive hypertension. Oxidative stress-induced telomerase inactivation, senescence, and apoptosis may represent important cellular mechanisms underlying ET-1-induced EPC reduction and dysfunction in low-renin, salt-sensitive hypertension. Hypertension with exacerbated systemic oxidative stress impairs EPC function, resulting in loss of its regenerative capacity, with obvious implications for endothelial dysfunction. Our finding on how the ET A /NADPH oxidase pathway and diminished antioxidants affect EPC function may provides a mechanistic basis for EPC genetic modification and therapeutic rejuvenation in hypertension.
Supplemental Methods
All the procedures in this study were approved by the University of Pittsburgh Institutional Animal Care and Use Committee and were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Animals
All ) rats were a generous gift from Dr. Cheryl E. Gariepy (University of Michigan, Ann Arbor, MI) 5 . In the present study, male ET B -/-and ET B +/+ rats (240-280 g) were used. ET B -/-rats are a novel single-locus genetic model of severe salt-sensitive hypertension, which express ETB receptors in adrenal glands and other adrenergic neurons but not in other tissues, such as the kidney, vascular endothelium, and vascular smooth muscle 5 .
DOCA-salt hypertensive rats and in vivo pharmacologic intervention
DOCA-salt hypertension was created in adult male SD rats as we previously described [6] [7] [8] . From the beginning of DOCA administration, some DOCA-salt rats received 4 weeks of ABT-627 (5 mg·kg -1 ·d -1 in drinking water, Abbott Laboratories), a selective ET A receptor antagonist 9 . Some DOCA-salt rats received diuretic trichlormethiazide (TCM, 10 mg·kg -1 ·d -1 in drinking water, Sigma) 10 . Some DOCA-salt rats received Apocynin (1.5 mmol/L in drinking water, Sigma), a NADPH oxidase inhibitor that impedes the assembly of the p47 phox and p67 phox within the membrane NADPH oxidase complex 7, 11, 12 . Our previous studies have shown that these doses of ABT-627 and Apocynin are effective in blocking the ET A receptors and the NADPH oxidase activity in vivo, respectively 8, 9, 11 . Average systolic blood pressure (SBP) of Sham and DOCA-salt rats was measured by the non-invasive tail-cuff method in conscious rats [6] [7] [8] . The peripheral blood of some rats was collected when the blood pressure was significantly elevated on Day 5 after DOCA-salt regimen. The peripheral blood and bone marrow of other rats were collected at Day 28 (4 weeks) following DOCA-salt regimen. The blood pressure of ET B -/-rats was monitored by radiotelemetry as we described previously 13 . Briefly, arterial blood pressure was monitored remotely using a commercially available radiotelemetry data acquisition program (Dataquest ART 3.1, Data Sciences International). Data were reported as 24-hour averages.
EPC isolation and characterization
Bone marrow-derived EPCs (BM-EPCs) were isolated from the femur and tibia of rats according to our recent publications [1] [2] [3] [4] . All assays were preformed after day 7. BM-EPCs were used in EPC function assays, Western blot analysis, NADPH oxidase activity and cell implantation. Freshly isolated MNCs and cultured BM-EPCs were characterized by flow cytometry according to our recent publications 1, 3, 4, 14 . To detect CD133, Flk-1, and VE-Cadherin, cells were incubated with rabbit anti-rat CD133 antibodies (Abcam), or rabbit anti-rat Flk-1 antibodies (Abcam), or mouse anti-rat VE-Cadherin antibodies (Santa Cruz) on ice for one hour right after pre-permeabilization with fresh-prepared methanol for l5 minutes. Then, cells were incubated with FITC-conjugated goat anti-rabbit secondary antibodies (Abcam) or PE-conjugated goat anti-mouse secondary antibodies (Santa Cruz) on ice for another one hour. 0.5% rabbit serum or 0.5% mouse serum was used for isotype staining. To detect CD34 or CD45, cells were incubated with mouse anti-rat CD34-PE antibodies (Santa Cruz) or mouse anti-rat CD45-PECy5 antibodies (BD Bioscience) on ice for one hour. Isotype specific conjugated anti-IgG was used as negative control. Quantifications of CD34+/Flk-1+ cells, CD34+/CD133+ cells, CD34+ cells, CD133+ cells, Flk-1+ cells, VE-Cadherin+ cells, and CD45+ cells were performed with a BD Vantage Flow Cytometer. Each analysis included at least 10,000 events.
Expressions of ET A and ET B receptors in EPCs by real-time PCR, immunocytochemistry, and Western blot analysis
ET A and ET B receptors on EPC were assessed by real-time RT-PCR, immunocytochemistry, and Western blot as described previously 15 . For all experiments, 18s was used as an internal control. 15 . Antibodies against the ET A and ET B receptors were from Alomone (Jerusalem, Israel). To verify the specificity of antibody binding, the primary antibody was incubated with the control peptide prior to application to cells. The absence of immunoreactivity confirmed the specificity of antibodies for ET receptors. The images were taken with a Zeiss Pascal confocal microscope at a resolution of 1,024×1,024 pixels. Western blots were performed by using primary antibodies directed against ET A receptors (1:200 dilution; Almone Labs) and ET B receptors (1:200 dilution; Almone Labs). To verify equal protein loading and transfer, the β-actin (1:10,000 dilution; Sigma) was used as the internal control Bands were visualized with an Odyssey Imager and quantified with Quantity One software (Bio-Rad) 15 .
EPC angiogenic function assays and pharmacologic treatments
EPC angiogenic function assays including tube formation capacity by Matrigel assay and adhesion function assay were described in detail in our previous studies 1, 3, 4 .
In vitro gene transfer
The propagation, purification, and titration of replication-incompetent adenoviral vectors were prepared as we described 7, 16 . After 7-days in culture, EPCs were transfected with the adenoviral vector encoding dominant-negative Rac1 (DNRac1) that inhibits endogenous NADPH oxidase subunit Rac1 16 or reporter gene β-galactosidase (β-gal) at a titer of 500 multiplicity of infection (MOI) in EGM-2 supplemented with 2% fetal bovine serum for 24 hours, followed by change of fresh 5% FBS EGM-2 1 . After 48 more hours of cultivation, transfected EPCs were subjected to ET-1 treatment as described above 16 .
Circulating EPC flow cytometry
Circulating EPCs were isolated according to our published methods 1, 3 . Briefly, freshly isolated peripheral blood mononuclear cells (PB-MNCs, 1×10 6 cells) were incubated with Flk-1 (2 μg/10 6 cells, Abcam) for one hour on ice, then incubated with a biotin-labeled goat anti-mouse IgG antibody (2.6 µg/10 6 cells, Jackson Immuno Research) for 30 minutes, followed by one hour incubation with APC-conjugated streptavidin (20 μl/10 6 cells, BD Biosciences) and PE-conjugated CD34 (1 μg/10 6 cells, Santa Cruz) on ice 17 . After washing and centrifugation, the cell pellets were suspended in 500 µl 5% BSA-PBS, and co-expressions of CD34 and Flk-1 were determined by flow cytometry (FACScan, Becton Dickenson) gating 30,000 events. Isotype specific conjugated anti-IgG was used as negative control.
Intracellular ROS measurement with dichlorofluorescein fluorescence (DCF) by flow cytometry
The intracellular ROS level in circulating EPCs was evaluated by DCF fluorescence using flow cytometry according to the manufacturer's recommended protocol and previous publications 18, 19 . 5- (6) NADPH oxidase enzymatic activity NADPH oxidase activity in EPCs was measured by a lucigenin-enhanced chemiluminescence assay, as we described with minor modifications 6, 20, 21 . Briefly, the enzyme activity was measured by lucigenin (5×10 -6 mol/L, Sigma) and indicated as the amount of O 2 -levels in the presence of their relative substrate NADPH (1×10 -4 mol/L, Sigma) 6 . No enzymatic activity could be detected in the absence of NADPH.
Western blot analyses
Western blots were performed by using primary antibodies directed against Rac1 (1:1,000 dilution; Abcam), gp91 phox (1:1,000 dilution; BD Biosciences), p22 phox (1:500 dilution; Santa Cruz), MnSOD (1:1,,000 dilution; BD Biosciences), CuZnSOD (1:10,000 dilution; Abcam), catalase (1:1,000 dilution; BD Biosciences), GPx-1 (1:500 dilution; Santa Cruz), p53 (1:2,500 dilution; Cell Signals), Bcl-2 (1:1,000 dilution; BD Biosciences), and Bax (1:1,000 dilution; BD Biosciences). To verify equal protein loading and transfer, β-actin (1:10,000 dilution; Sigma) was used as the internal control. Bands were visualized with an Odyssey Imager and quantified with Quantity One software (Bio-Rad) 1, 3, 4, 14 .
Senescence assay
EPC senescence was determined by acidic β-galactosidase staining kit (Sigma), according to the manufacturer's recommended protocol and our recent publication 4 .
Apoptosis assay EPC apoptosis was determined by DeadEnd Fluorometric TUNEL System staining (Promega) according to the manufacturer's instructions 22 . Cell nuclei were co-stained with the fluorescent dye Hoechst33528
1 . The green-staining nuclei (TUNEL-positive cells) were detected under a fluorescence microscope equipped with a digital camera and the MetaMorph 6.1 image analysis software (Universal Imaging Corporation) 22 . TUNEL-positive cells were counted under ten random high power fields (magnifications 200×) of each sample.
Telomerase activity
Telomeric Repeat Amplification Protocol Assay (TRAP Assay) was employed, through which the telomerase reaction product is amplified by PCR 23 . Telomerase activity was measured with 2 µg proteins by the Telo TAGGG Telomerase PCR ELISA plus Kit (Roche, USA) according to the manufacturer's instructions 23 . The absorbance values were determined by using a Micro-plate reader; the absorbance of the samples was measured at 450 nm wavelengths.
Hindlimb ischemia and in vivo EPC therapy
Hindlimb ischemia was carried out in Sham or DOCA-salt rats on Day 14 after DOCA or Sham surgery. Briefly, the right femoral artery and its branches were exposed proximal to the origin of the arterial popliteal, ligated, and the incision was closed in layers. The left femoral artery and its branches were only exposed without dissection, which served as non-ischemia control 24, 25 . DOCA-salt rats were randomly divided into five groups, which received PBS (vehicle) or BrdU-labeled EPC implantation: 1) DOCA rats + PBS, 2) DOCA rats + sham rat-derived EPCs (Sham-EPCs), 3) DOCA rats + DOCA rat-derived EPCs (DOCA-EPCs), 4) DOCA rats + ABT treated DOCA rat-derived EPCs (ABT-EPCs), and 5) DOCA rats + DNRac-1 treated DOCA rat-derived EPCs (DNRac1-EPCs). In the vehicle or EPC implantation groups, 100 μl of PBS or 1×10 7 EPCs in 100μl, was randomly injected intramuscularly into anterior tibial muscle at the six points with a 27-gauge needle 24 hours after femoral artery dissection 25 . Hindlimb blood flow was measured before, right after, 7 days after, and 14 days after right femoral artery ligations. The rats were pre-warmed for 10 minutes, and then placed on 37°C heated pads through the measurement 26 . The hindlimb blood flow was measured by a Laser Doppler Perfusion Imager (LDPI) as described previously 24 . Low or no perfusion is displayed as dark blue, whereas the high perfusion is displayed as yellow or red. The blood flow images were measured with Image-Pro Plug 5.0 and expressed as perfusion ratio of ischemic hindlimb to non-ischemic limb.
Immunohistochemistry and measurement of capillary density
The effect of EPC implantation (or PBS) on neovascularization was assessed under light microscopy by measuring of the number of capillaries in sections taken from the ischemic muscles 24, 25 . Tissue specimens were obtained from anterior tibial muscles on day 14. This muscle was chosen because it is one of the principal muscles of the lower limb and is commonly used to evaluate the distal reperfusion after the femoral arteries are excised. The muscle was fixed in 10% Formalin and embedded in paraffin. Sections (5 μm) were de-paraffinized and incubated with a goat anti-human CD31 antibody (1:100 dilution, Santa Cruz). Antibody distribution was visualized with the use of the avidin-biotin-complex technique and Vector Red chromogenic substrate (Vector Laboratories), followed by counterstaining with hematoxylin. Negative controls were performed by avoiding the primary antibodies. Capillaries were identified by positive staining for CD31. Five fields from each sample were randomly selected and photographed with a digital camera (Olympus), and visible capillaries (positive for CD31) were counted. Capillary density was expressed as the number of capillaries per square millimeter 27 . To investigate whether implanted EPCs were incorporated the capillaries, BrdU labeled EPCs were injected intramuscularly into anterior tibial muscle. On Day 14, the anterior tibial muscle was collected and fixed with 10% Formalin. The sections were incubated with BrdU antibody (1:50 dilution, Amersham Biosciences) and CD31 antibody (1:50 dilution, Santa Cruz), followed by secondary antibodies anti-mouse PE and anti-goat FITC, respectively. Implanted EPCs were identified as BrdU positive cells 28 .
Data analysis
All obtained values were expressed as mean ± SEM. A GraphPad Prism (Version 5) was used for data analysis. Statistical analysis between two groups was performed using the Student's two-tailed unpaired t test. A one-way ANOVA was used in data analysis when more than two groups were compared, followed by the Bonferroni's procedure to control the Type I error. A two-way Repeated-measures ANOVA followed by the Bonferroni's post-test was used to analyze blood flow perfusion in hindlimb ischemia models, and a significant overall difference was detected 10, 16. Specifically, the group of DOCA-salt rats was compared with the Sham group, to determine the effect of DOCA-salt treatment on EPC functions and subsequent molecular changes. The groups of ABT-627 + DOCA and Apocynin + DOCA were compared with DOCA-salt rats to determine the effects of the blockade of ET A /NADPH oxidase pathway on EPC functions and subsequent molecular changes. A value of P<0.05 was considered as a statistically significant finding.
Results
Characterization of bone marrow-derived EPCs
To characterize bone marrow derived EPCs, the stem cell markers (CD34, CD133), endothelial cell markers (Flk-1, VE-cadherin) and a hematopoietic cell marker (CD45) were examined by flow cytometry according to the procedure described in our recent publications [1] [2] [3] [4] . The cell populations were showed in Supplemental Table 1 and Table 2 . These data suggest that EPCs cultured for 7 days (termed as early-cultured EPCs) are heterogeneous in nature, and they contain significantly higher percentage of progenitor cells with endothelial differentiating potential compared with the freshly isolated mononuclear cells. The early-cultured EPCs were also identified by Dil-acLDL/lectin double staining (Supplemental Fig. S3A ) and the expressions of endothelial lineage markers between HUVECs and EPCs cultured for 7 days. Similar to HUVECs, early-cultured EPCs expressed endothelial markers including Flk-1, VE-cadherin, and eNOS (Supplemental Fig. S3B ).
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